Valeant to acquire Ortho Dermatologics

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Singapore Seeking Pharmaceutical Tariff Concessions from US

The deputy prime minister and trade minister of Singapore,...

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Valeant Pharmaceuticals International announced today that Valeant’s subsidiaries, Valeant Pharmaceuticals North America LLC (VPNA) and Valeant International (Barbados) SRL (VIB), have signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc.

Valeant will pay Janssen $345 million for the assets, which includes prescription brands RETIN-A MICRO®, ERTACZO®, and RENOVA®. Total revenue for the product portfolio was approximately $150 million in 2010. The transaction is subject to certain closing conditions and regulatory approvals and is expected to be accretive in 2011.

“With the combination of this transaction and other recently announced transactions, Valeant is well on its way to being one of the leading companies in dermatology,” stated J. Michael Pearson, chairman and chief executive officer. “We believe that dermatology remains an attractive therapeutic area for Valeant and we are pleased to able to add another strong franchise to our growing operations.”

Latest stories

Related stories

Singapore Seeking Pharmaceutical Tariff Concessions from US

The deputy prime minister and trade minister of Singapore,...

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back